Less than two weeks in, Trump is already waffling on that stand. His softening — and what it portends — is an opportunity that opponents cannot afford to pass up.

It turns out that it took only one visit from the pharmaceutical industry to get Trump singing a different tune. As recently as three weeks ago, Trump said drug companies were “getting away with murder.” He added, “We’re the largest buyer of drugs in the world, and yet we don’t bid properly.” On Tuesday, though, meeting with the bosses of some of the world’s largest drug companies, he shifted the blame elsewhere:

AD

AD

So what I want, we have to get lower prices, we have to get even better innovation and I want you to move your companies back into the United States. And I want you to manufacture in the United States. We’re going to be lowering taxes, we’re going to be getting rid of regulations that are unnecessary.

Instead of getting tough with these companies, Trump is offering tax cuts to businesses that already make billions in profits every year. It’s true that Sean Spicer insisted later that Trump still is considering negotiated pricing. But the fact is that, when facing members of the industry, Trump refused to confront them. Furthermore, it’s well-known by now that “Trump tends to echo the words of the last person with whom he spoke” and there aren’t exactly a lot of pro-health-care consumer voices in the White House. All this suggests that when the chips are down, Trump is going to side with businesses over consumers.